期刊文献+

四种疗法治疗幽门螺杆菌阳性消化性溃疡疗效分析 被引量:2

Therapeutic Effect of Four Kinds of Therapy on Helicobacter Pylori Positive Peptic Ulcer
下载PDF
导出
摘要 目的使用四种不同疗法治疗幽门螺杆菌阳性消化性溃疡并比较其疗效。方法选取2014年9月~2017年5月到我院就诊的245例幽门螺杆菌阳性消化性溃疡的患者,依给药方式的不同分为四组,分别为组1雷贝拉唑四联疗法治疗组60例,组2雷贝拉唑三联疗法治疗组60例,组3奥美拉唑四联疗法治疗组62例,组4奥美拉唑三联疗法治疗组63例,比较4种不同给药方式对幽门螺杆菌阳性消化性溃疡的疗效。结果组1、组2治疗总有效率均为98.33%,组3总有效率为95.16%,组4总有效率为93.65%。从整体治疗效果上看,雷贝拉唑优于奥美拉唑,差异具有统计学意义(P<0.05)。在雷贝拉唑治疗组中,雷贝拉唑四联疗法有效率为91.30%,雷贝拉唑三联疗法有效率为73.80%,二者具有统计学意义(P<0.05);在奥美拉唑治疗组中,奥美拉唑四联疗法有效率为73.91%,奥美拉唑三联疗法有效率为58.12%,二者间有统计学意义(P<0.05);比较雷贝拉唑四联疗法和奥美拉唑四联疗法的有效率,差异具有统计学意义(P<0.05),雷贝拉唑四联疗法优于奥美拉唑四联疗法;比较雷贝拉唑三联疗法和奥美拉唑三联疗法的有效率,差异具有统计学意义(P<0.05),雷贝拉唑三联疗法疗效优于奥美拉唑三联疗法。在幽门螺旋杆菌的清除上,雷贝拉唑优于奥美拉唑,四联疗法优于三联疗法。结论在治疗幽门螺杆菌阳性消化性溃疡中,雷贝拉唑四联疗法表现出最佳的治疗效果。 Objective To use four different therapies to treat Helicobacter pylori-positive peptic ulcer and compare its efficacy.Methods A total of 245 patients with Helicobacter pylori-positive peptic ulcer who were admitted to our hospital from September 2014 to May 2017 were divided into four groups according to the different methods of administration.There were 60 cases of group 1 rabeprazole quadruple therapy group,group 2 of rabeprazole triple therapy group 60 cases,group 3 of omeprazole quadruple therapy group 62 cases,group 4 omeprazole triple therapy treatment group 63 cases,compared four different modes of administration of Helicobacter pylori-positive peptic ulcer efficacy.Results The total effective rate of group 1 and group 2 was 98.33%,the total effective rate of group 3 was 95.16%,and the total effective rate of group 4 was 93.65%.In terms of overall therapeutic effect,rabeprazole was superior to omeprazole,with a statistically significant difference(P<0.05).In rabeprazole-treated group,the effective rate of rabeprazole quadruple therapy was 91.30%,and the effective rate of rabeprazole triple therapy was 73.80%,both of which were statistically significant(P<0.05);In the omeprazole treatment group,the effective rate of omeprazole quadruple therapy was 73.91%,and the effective rate of omeprazole triple therapy was 58.12%.There was a statistically significant difference between them(P<0.05);Comparing the efficacy of rabeprazole quadruple therapy and omeprazole quadruple therapy,the difference was statistically significant(P<0.05),rabeprazole quadruple therapy was superior to omeprazole quadruple therapy;Comparing the effectiveness of rabeprazole triple therapy and omeprazole triple therapy,the difference was statistically significant(P<0.05).Rabeprazole triple therapy was superior to omeprazole triple therapy.In the eradication of Helicobacter pylori,rabeprazole is superior to omeprazole,and quadruple therapy is superior to triple therapy.Conclusion In the treatment of Helicobacter pylori-positive peptic ulcer,rabeprazole quadruple therapy showed the best therapeutic effect.
作者 夏铭 张正坤 曾海龙 王伟 XIA Ming;ZHANG Zheng-kun;ZENG Hai-long;WANG Wei(Department of Gastroenterology,Jiuquan Municipal People's Hospital,Jiuquan 735000,Gansu,China)
出处 《医学信息》 2018年第11期18-21,共4页 Journal of Medical Information
关键词 雷贝拉唑 奥美拉唑 幽门螺旋杆菌 消化性溃疡 Rabeprazole Omeprazole Helicobacter pylori Peptic ulcer
  • 相关文献

参考文献5

二级参考文献49

  • 1Qin-Juan Sun, Xiao Liang, Qing Zheng, Wei-Qi Gu, WenZhong Liu, Shu-Dong Xiao, Hong Lu.Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai[J].World Journal of Gastroenterology,2010,16(40):5118-5121. 被引量:90
  • 2崔梅花,杨友鹏,岳林,傅怡,乙国兴,牟方宏,杨桂彬,朱红霞,张秀丽.幽门螺杆菌血清抗体对埃索美拉唑四联疗法根除效果的影响研究[J].中国全科医学,2013,16(8):850-853. 被引量:16
  • 3Feng Ji,Zi-Wei Wang,Jian-Wen Ning,Qun-Yan Wang,Jian-Yong Chen,You-Ming Li.Effect of drug treatment on hyperplastic gastric polyps infected with Helicobacter pylorh A randomized, controlled trial[J].World Journal of Gastroenterology,2006,12(11):1770-1773. 被引量:39
  • 4Marino ML, Fais S, Djavaheri MM, et al. Proton pump inhibition in- duces autophagy as a survival mechanism following oxidative sa'ess in human melanoma cells [J]. Cell Death Dis, 2010, 1(10): 87-89.
  • 5Hassan AM, Andersson T, Bredberg E, et al. Pharmacokineties of esomerparzole after oral and intervenous administstion of single and repeated doses to health subjects [J]. Eur J Clin Pharmacol, 2011, 56(2): 665-670.
  • 6Hunt RH,Xiao SD,Megraud F,et al.Helicobacter pylori in developing countries.World Gastroenterology Organisation Global Guideline [J].J Gastrointestin Liver Dis,2011,20(3):299-304.
  • 7Fock KM,Katelaris P,Sugano K,et al.Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection [J].J Gastroenterol Hepatol,2009,24(10):1587-1600.
  • 8Malfertheiner P,Megraud F,O' Morain CA,et al.Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report [ J ].Gut,2012,61(5):646-664.
  • 9Couturier MR,Marshall BJ,Goodman K J,et al.Helicobacter pylori diagnostics and treatment:could a lack of universal consensus be the best consensus? [ J ].Clin Chem,2014,60(4):589-594.
  • 10Su P,Li Y,Li H,et al.Antibiotic resistance of Helicobacter pflori isolated in the Southeast coastal region of China [J].Helicobacter,2013,18(4):274-279.

共引文献68

同被引文献22

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部